Merck Animal Health Introduces BIOMARK® IS1001 MUX Multiplexing Transceiver

The updated stationary reader platform connects up to six antennas for improved performance to evaluate fish passage and movement

RAHWAY, N.J., March 18, 2024 – Merck Animal Health, known as MSD Animal Health outside of the United States and Canada, a division of Merck & Co., Inc., Rahway, N.J., USA (NYSE:MRK), today announced the introduction of the BIOMARK^® IS1001 MUX multiplexing transceiver. This updated stationary reader platform connects up to six separate antennas to deliver superior performance for the assessment of fish movement and passage in riverine environments.

            The IS1001 MUX is specifically designed for fisheries’ managers and biologists who are part of federal, state, university or tribal research programs in the U.S. and Canada. As an upgrade from its predecessor, the FS1001M, this device takes advantage of the improved performance of the IS1001 reader and the ability to decode FDX-B and HDX PIT tags. It can be used for instream or facility applications.

            “Merck Animal Health is committed to providing innovative solutions for the aquaculture industry, and our Biomark brand has specialized in building customized PIT tag detection systems for more than 30 years,” said Steve Anglea, senior project manager for BIOMARK with Merck Animal Health. “The IS1001 MUX delivers enhanced performance over earlier generations of multiplexers, and it streamlines system installations and reduces risk for our customers by centralizing electronics on the bank instead of relying on readers attached to antennas that could be lost in the river.”

            Key features of the IS1001 MUX include:

• Multiplexes up to six separate antennas;
• Decodes FDX-B and HDX PIT tags;
• Ability to store more than 78,000 tag codes in the internal memory or real-time communication;
• Compatible with BIOMARK’s remote data collection system;
• Flexible and configurable to support a wide array of applications.

For more information about the BIOMARK IS1001 MUX and other innovative aqua solutions from Merck Animal Health, contact customer service at (208) 275-0011 or visit Biomark.com.

Merck Animal Health introduces the BIOMARK^® IS1001 MUX multiplexing transceiver. This updated stationary reader platform connects up to six separate antennas to deliver superior performance to evaluate fish movement and passage in riverine environments.

About Merck Animal Health

At Merck, known as MSD outside of the United States and Canada, we are unified around our purpose: We use the power of leading-edge science to save and improve lives around the world. For more than a century, we’ve been at the forefront of research, bringing forward medicines, vaccines and innovative health solutions for the world’s most challenging diseases. Merck Animal Health, a division of Merck & Co., Inc., Rahway, N.J., USA, is the global animal health business of Merck. Through its commitment to The Science of Healthier Animals^®, Merck Animal Health offers veterinarians, farmers, producers, pet owners and governments one of the widest ranges of veterinary pharmaceuticals, vaccines and health management solutions and services as well as an extensive suite of connected technology that includes identification, traceability and monitoring products. Merck Animal Health is dedicated to preserving and improving the health, well-being and performance of animals and the people who care for them. It invests extensively in dynamic and comprehensive R&D resources and a modern, global supply chain. Merck Animal Health is present in more than 50 countries, while its products are available in some 150 markets. For more information, visit www.merck-animal-health.com and connect with us on LinkedIn, Facebook, X (formerly Twitter) and Instagram.

Forward-Looking Statement of Merck & Co., Inc., Rahway, N.J., USA

            This news release of Merck & Co., Inc., Rahway, N.J., USA (the “company”) includes “forward-looking statements” within the meaning of the safe harbor provisions of the U.S. Private Securities Litigation Reform Act of 1995. These statements are based upon the current beliefs and expectations of the company’s management and are subject to significant risks and uncertainties. If underlying assumptions prove inaccurate or risks or uncertainties materialize, actual results may differ materially from those set forth in the forward-looking statements.

Risks and uncertainties include but are not limited to, general industry conditions and competition; general economic factors, including interest rate and currency exchange rate fluctuations; the impact of pharmaceutical industry regulation and health care legislation in the United States and internationally; global trends toward health care cost containment; technological advances, new products and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approval; the company’s ability to accurately predict future market conditions; manufacturing difficulties or delays; financial instability of international economies and sovereign risk; dependence on the effectiveness of the company’s patents and other protections for innovative products; and the exposure to litigation, including patent litigation, and/or regulatory actions.

The company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Additional factors that could cause results to differ materially from those described in the forward-looking statements can be found in the company’s Annual Report on Form 10-K for the year ended December 31, 2023 and the company’s other filings with the Securities and Exchange Commission (SEC) available at the SEC’s Internet site (www.sec.gov).

---